Diabetic ketoacidosis
18 results
1 - 18
Treatment with SGLT2 inhibitors rarely results in diabetic ketoacidosis- Type 1 diabetes in fair to good control not associated with reduced school performance in children
- Low-dose insulin at least as good as standard doses in biochemical control of kids with DKA
- No benefit from screening for asymptomatic CAD in type 2 diabetes
- Sotagliflozin reduces hospitalizations and urgent visits for heart failure, but has no mortality benefit (SCORED)
- Insulin pumps lower A1C more than multiple insulin doses in patients with type 2 DM (OpT2mise)
- SGLT2 inhibitors = little effect on glycemic control or all-cause mortality, but decrease CV deaths in older adults with T2DM plus heart failure
- Limited meta-analysis suggests SGLT2 inhibitors improve cardiovascular outcomes in patients with T2DM + atherosclerosis
- Dapagliflozin in high-risk T2DM reduces hospitalization for HF, but does not reduce death, MI, or stroke (DECLARE-TIMI 58)
- Limited SR demonstrates SGLT2 inhibitors improve outcomes in adults with heart failure